The spectacular IPO of Sinopharm Group in September 2009 started something: 23 China life science enterprises have become public companies in the last year, listing their shares on China mainland exchanges or in Hong Kong. Although eight of the deals were worth less than $100 million, their total value is $5.4 billion, showing that investors think the outlook for China life science is very bright. More details...